Windlas Biotech Limited has fixed Thursday, July 16, 2026, as the record date to determine members eligible for a final dividend of ₹6.30 per equity share for the financial year ended March 31, 2026. The dividend, recommended at 126% of the face value of ₹5 each, is subject to shareholder approval at the upcoming 25th Annual General Meeting (AGM) scheduled for July 23, 2026. The payment will be made within 30 days from the date of declaration at the AGM, subject to tax deduction at source.

AGM and E-Voting Details

The 25th AGM will be held on Thursday, July 23, 2026, at 1:00 P.M. via Video Conferencing (VC) and Other Audio Visual Means (OAVM), in compliance with Ministry of Corporate Affairs (MCA) Circular No. 20/2020 and General Circular No. 03/2025. Members attending through VC will be counted for quorum purposes under Section 103 of the Companies Act, 2013. Remote e-voting will be available from July 20, 2026 (9:00 A.M.) to July 22, 2026 (5:00 P.M.), facilitated by MUFG Intime India Private Limited.

Agenda for the Meeting

Key agenda items include the adoption of audited standalone and consolidated financial statements for FY26, the declaration of the final dividend, and the re-appointment of Mr. Hitesh Windlass and Mrs. Prachi Jain Windlass as directors liable to retire by rotation. Additionally, the meeting will seek ratification for the remuneration of the Cost Auditor, M/s Sourabh Jain & Associates, at ₹60,000 excluding GST for FY27. Shareholders will also vote on the appointment of Dr. Tarashree Singhal as an Independent Woman Director for a five-year term from May 5, 2026, to May 4, 2031.

Director Re-appointments

Mr. Hitesh Windlass (DIN: 02030941), Managing Director, and Mrs. Prachi Jain Windlass (DIN: 06661073), Non-Executive Director, are eligible for re-appointment. Mr. Hitesh Windlass has been with the company since January 21, 2008, and holds a bachelor's degree in ceramic engineering from IIT Banaras Hindu University and an MBA from the University of Chicago. Mrs. Prachi Jain Windlass, appointed on May 3, 2021, holds a bachelor's degree in technology from IIT Delhi and master's degrees from the University of Southern California and the University of Chicago.

Windlas Biotech Limited has scheduled a series of meetings with analysts and institutional investors between July 2 and July 7, 2026, to discuss its performance and strategy. The company will engage with entities including Vara Capital, Apricus Wealth Investment Managers, Trust Mutual Fund, Baring Private Equity Partners India, and Vaikarya Investment Management during these sessions. These interactions are part of the company's ongoing investor relations efforts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Windlas Biotech stated that discussions will rely solely on publicly available documents. The company explicitly confirmed that no unpublished price sensitive information (UPSI) will be shared during these interactions. Ananta Narayan Panda, Company Secretary & Compliance Officer, signed the intimation on June 24, 2026.

Meeting Schedule

The company noted that changes to the schedule may occur due to exigencies on the part of investors, analysts, or the company.